TrustFinance is trustworthy and accurate information you can rely on. If you are looking for financial business information, this is the place for you. All-in-One source for financial business information. Our priority is our reliability.

TrustFinance Global Insights
Mar 16, 2026
1 min read
19

Option Therapeutics, ticker symbol OPTN, has submitted a revised filing for its Initial Public Offering. The company now plans to offer 1,818,182 shares to the public, a reduction from its previous plan.
The new offering size represents a decrease from the initially indicated 2.27 million shares. Despite the reduction in share volume, the company has maintained its target price range of $10 to $12 per share for the offering.
A downsized IPO often reflects a company's adjustment to current market sentiment or investor demand. This change means the total capital raised will be lower than first projected, which could impact the company's funding for future operations and research.
Investors will monitor the market's reception to this smaller offering. The final IPO pricing and subsequent trading performance will serve as important indicators for sentiment towards Option Therapeutics and the broader biotechnology sector.
Q: How many shares is Option Therapeutics now offering?
A: The company has filed to offer 1,818,182 shares.
Q: What is the price range for the OPTN IPO?
A: The price range remains unchanged at $10 to $12 per share.
Source: Investing.com

TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Related Articles

17 Mar 2026
Audi Profit Drops 14% Amid US Tariff Impact